143 related articles for article (PubMed ID: 9143870)
1. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations.
Sagawa K; Mohri K; Shimada S; Shimizu M; Muramatsu J
Eur J Clin Pharmacol; 1997; 52(1):65-9. PubMed ID: 9143870
[TBL] [Abstract][Full Text] [Related]
2. Disopyramide concentrations in saliva.
Aitio ML; Virtanen R; Lammintausta R
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of disopyramide in normal volunteers using unbound concentration.
Braun J; Sörgel F; Gluth WP; Oie S
Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
Aso R; Ohashi K; Katoh T; Ogata H
Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.
Vanstraelen K; Maertens J; Augustijns P; Lagrou K; de Loor H; Mols R; Annaert P; Malfroot A; Spriet I
Clin Pharmacokinet; 2015 Nov; 54(11):1151-60. PubMed ID: 25910879
[TBL] [Abstract][Full Text] [Related]
6. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
7. Immediate- versus controlled-release disopyramide: importance of saturable binding.
Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
[TBL] [Abstract][Full Text] [Related]
8. Saliva concentrations of disopyramide cannot substitute the drug's plasma concentrations.
Cordonnier J; Van den Heede M; Heyndrickx A
J Anal Toxicol; 1987; 11(4):179-81. PubMed ID: 3626531
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective analysis of disopyramide and mono-N-dealkyldisopyramide in plasma and urine by high-performance liquid chromatography on an amylose-derived chiral stationary phase.
Bortocan R; Lanchote VL; Cesarino EJ; Bonato PS
J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(2):299-306. PubMed ID: 10993518
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide.
Lima JJ; Shields BJ; Howell LH; MacKichan JJ
Ther Drug Monit; 1984; 6(2):203-10. PubMed ID: 6377599
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man.
Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD
J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
[TBL] [Abstract][Full Text] [Related]
13. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations.
Echizen H; Ishikawa S; Koike K; Ishizaki T
Ther Drug Monit; 1995 Apr; 17(2):145-52. PubMed ID: 7624903
[TBL] [Abstract][Full Text] [Related]
14. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Giacomini KM; Blaschke TF
Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
[TBL] [Abstract][Full Text] [Related]
16. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
17. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
Raghow G; Meyer MC; Straughn AB
Ther Drug Monit; 1985; 7(4):466-71. PubMed ID: 3909539
[TBL] [Abstract][Full Text] [Related]
18. A simple method for the simulation of unbound serum disopyramide concentration in patients.
Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.
Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
Biopharm Drug Dispos; 1993 Jul; 14(5):409-18. PubMed ID: 8218959
[TBL] [Abstract][Full Text] [Related]
20. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
